Migrating from On Premise to AWS: How Pharma Companies Can Protect Research Data with AWS Data Migration from On Premise to Cloud

Pharmaceutical companies manage valuable research data throughout drug discovery, laboratory experiments, preclinical studies, clinical trials, and regulatory submissions. This information includes experimental results, molecular datasets, clinical records, laboratory documentation, and proprietary intellectual property. Protecting these assets is essential for maintaining research integrity, meeting regulatory obligations, and safeguarding competitive advantage.

However, traditional on-premises infrastructure can make it challenging to manage growing data volumes, maintain consistent security controls, and provide researchers with timely access to information. Amazon Web Services (AWS) offers cloud capabilities that pharmaceutical organizations can use to modernize their data environments while maintaining appropriate safeguards.

Migrating from On Premise to AWS requires more than transferring files and databases. Pharma companies must consider data security, application dependencies, regulatory requirements, and research continuity. With a structured migration strategy, organizations can move suitable workloads to AWS while protecting sensitive research information.

1. Assess Research Data Before Migration

Before beginning migration, pharmaceutical companies need to understand where research data resides and how applications use it. Information may be distributed across laboratory information management systems (LIMS), research databases, electronic laboratory notebooks, clinical trial platforms, and document repositories.

A comprehensive assessment should identify data types, sensitivity levels, application dependencies, storage requirements, and retention obligations.

For example, proprietary drug discovery data may require strict access restrictions, while clinical trial records may involve additional privacy and documentation requirements. Understanding these differences helps organizations establish appropriate migration priorities.

The assessment should also identify outdated applications, unsupported infrastructure, and systems that require modernization before moving to the cloud.

A clear inventory gives IT and research teams a practical starting point for planning the migration, selecting suitable AWS services, and identifying risks before transferring critical datasets.

2. Strengthen Data Security with AWS

Research data represents a valuable business asset, making security a central consideration throughout migration and ongoing cloud operations.

AWS provides services that organizations can configure to protect information. Amazon Simple Storage Service (Amazon S3) supports object storage, while AWS Identity and Access Management (IAM) helps control access to AWS resources. Encryption capabilities can protect information during transfer and storage.

Pharmaceutical companies should apply least-privilege access, restrict permissions according to job responsibilities, and protect credentials and encryption keys. Logging and monitoring can also help teams investigate unusual activity and identify potential security issues.

Security requirements should be defined before migration begins and validated before workloads enter production.

Using AWS does not automatically make a research environment secure or compliant. Organizations must configure services appropriately, monitor access, document controls, and maintain oversight as applications and datasets change.

3. Choose the Right AWS Data Migration Tools

Different research workloads require different migration methods. The appropriate tools depend on data volume, source infrastructure, connectivity, database compatibility, and downtime requirements.

AWS Database Migration Service (AWS DMS) supports migrations between supported source and target databases. Depending on the configuration, ongoing database changes can also be replicated to help maintain synchronization during migration.

AWS DataSync helps transfer files and other data between on-premises storage and supported AWS storage services.

Amazon S3 can store research files, datasets, documents, and other suitable content. Access permissions, encryption, and lifecycle policies can be configured according to organizational requirements.

For large transfers or locations with limited network connectivity, pharmaceutical companies may also assess AWS Snow Family options, subject to current availability and suitability.

Selecting the right services helps organizations manage data transfers efficiently while accounting for technical dependencies and security requirements.

4. Maintain Research Data Integrity

Successful data transfer is not simply about moving files to a new location. Research information must remain accurate, complete, and usable after migration.

Missing records, corrupted files, or inconsistent database entries can affect research analysis, reproducibility, and subsequent investigations.

Before migration, teams should establish validation procedures and define acceptance criteria. Depending on the workload, these may include record-count comparisons, checksums, data sampling, schema validation, and application-level testing.

Organizations should also preserve relevant metadata, timestamps, file relationships, and audit records where required.

For systems that continue receiving updates during migration, the transition plan should explain how new data will be synchronized and when the target environment becomes authoritative.

After migration, researchers and application owners should verify that datasets are accessible, records remain consistent, and connected applications function correctly. These checks provide evidence that the migrated environment meets the organization's data integrity requirements.

5. Address Pharmaceutical Compliance Requirements

Pharmaceutical companies may operate systems subject to regulatory and quality requirements, depending on their intended use. Certain research, clinical, and manufacturing activities may involve Good Practice requirements or electronic-record controls under applicable regulations, including FDA 21 CFR Part 11 where relevant.

Before migrating a regulated application, organizations should determine which requirements apply and whether the planned changes affect its validated state.

Important considerations include access controls, audit trails, record retention, change management, system validation, and documented testing.

Migration activities should be coordinated with quality assurance, regulatory, research, and IT teams. These stakeholders can help determine what documentation and validation evidence must be maintained before the migrated system is approved for use.

AWS provides technical capabilities that can support appropriately designed environments, but compliance depends on the complete system, including configuration, procedures, documentation, and organizational controls.

6. Minimize Disruption to Research Operations

Researchers depend on timely access to datasets, laboratory applications, and analytical tools. An unplanned interruption can delay experiments, disrupt collaboration, or affect scheduled research activities.

A phased migration can help pharmaceutical companies manage these risks. Organizations may begin with suitable lower-risk datasets, validate the process, and apply lessons learned before migrating more complex workloads.

Before cutover, teams should test application functionality, data access, integrations, and expected performance. They should also establish maintenance windows, communication procedures, and rollback plans.

Where technically appropriate, an initial bulk transfer followed by incremental synchronization can reduce the amount of data that needs to move during the final transition.

These practices help maintain research continuity while allowing organizations to modernize their infrastructure systematically.

7. Plan for Ongoing Monitoring and Recovery

Protecting research data does not end when migration is complete. Pharmaceutical organizations need ongoing controls to manage access, monitor activity, maintain backups, and respond to incidents.

AWS capabilities can support logging, monitoring, backup, and recovery when appropriately configured. Organizations should establish recovery time objectives (RTOs) and recovery point objectives (RPOs) according to the importance of each workload.

Regular recovery tests help confirm that applications and datasets can be restored as expected. Access reviews and configuration checks help identify security gaps as the environment evolves.

Pharma companies should also monitor storage utilization, retention requirements, and cloud expenditure as research data grows. These activities help keep the environment secure, manageable, and aligned with operational needs.

Conclusion

Migrating from On Premise to AWS gives pharmaceutical companies an opportunity to modernize their data infrastructure, improve accessibility, and support evolving research requirements. However, the transition must protect intellectual property, maintain data integrity, and address applicable regulatory obligations.

Through careful assessment, suitable AWS migration tools, secure data transfers, validation, and ongoing monitoring, pharmaceutical organizations can build a more manageable cloud environment.

The objective of AWS Data Migration from On Premise to Cloud is not simply to relocate research data. It is to protect the confidentiality and integrity of research while establishing a flexible technology foundation that supports pharmaceutical innovation